KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses (2016 - 2026)

Halozyme Therapeutics has reported Accumulated Expenses over the past 17 years, most recently at $140.4 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 7.72% to $140.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $140.4 million through Mar 2026, up 7.72% year-over-year, with the annual reading at $156.2 million for FY2025, 21.22% up from the prior year.
  • Accumulated Expenses was $140.4 million for Q1 2026 at Halozyme Therapeutics, down from $156.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $156.2 million in Q4 2025 and troughed at $19.1 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $105.4 million (2023), against an average of $104.3 million.
  • Year-over-year, Accumulated Expenses soared 336.34% in 2022 and then dropped 1.98% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $99.8 million in 2022, then increased by 0.92% to $100.7 million in 2023, then increased by 27.98% to $128.9 million in 2024, then grew by 21.22% to $156.2 million in 2025, then dropped by 10.13% to $140.4 million in 2026.
  • Per Business Quant, the three most recent readings for HALO's Accumulated Expenses are $140.4 million (Q1 2026), $156.2 million (Q4 2025), and $111.2 million (Q3 2025).